HUP0100500A2 - Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása - Google Patents

Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása

Info

Publication number
HUP0100500A2
HUP0100500A2 HU0100500A HUP0100500A HUP0100500A2 HU P0100500 A2 HUP0100500 A2 HU P0100500A2 HU 0100500 A HU0100500 A HU 0100500A HU P0100500 A HUP0100500 A HU P0100500A HU P0100500 A2 HUP0100500 A2 HU P0100500A2
Authority
HU
Hungary
Prior art keywords
hydrate
ethoxy
benzyl
amino
methyl
Prior art date
Application number
HU0100500A
Other languages
English (en)
Inventor
Paul David James Blackler
David C. Lee
Michael John Sasse
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of HUP0100500A2 publication Critical patent/HUP0100500A2/hu
Publication of HUP0100500A3 publication Critical patent/HUP0100500A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}- benzil]-2,4-dioxo-tiazolidin-maleinsav-sónak egy hidrátja vonatkozik, amelyreaz jellemző, hogy (i) 0,2-1,1 tömeg% vizet tartalmaz; és (ii) olyaninfravörös spektrumot eredményez, amely 764 és 579 cm-1- nél tartalmazcsúcsokat; A találmány kiterjed a hidrát előállítási eljárására,valamint gyógyászati alkalmazására diabetes mellitusz bizonyosszövődményeinek kezelésénél. Ó
HU0100500A 1997-12-16 1998-12-14 Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino) ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, process for its preparation and its pharmaceutical use HUP0100500A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726568.0A GB9726568D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (2)

Publication Number Publication Date
HUP0100500A2 true HUP0100500A2 (hu) 2002-05-29
HUP0100500A3 HUP0100500A3 (en) 2002-08-28

Family

ID=10823694

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100500A HUP0100500A3 (en) 1997-12-16 1998-12-14 Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino) ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, process for its preparation and its pharmaceutical use

Country Status (37)

Country Link
US (2) US7045633B2 (hu)
EP (1) EP1045847A1 (hu)
JP (1) JP2002508372A (hu)
KR (1) KR100549143B1 (hu)
CN (3) CN101412714A (hu)
AP (1) AP1441A (hu)
AR (2) AR017213A1 (hu)
AU (1) AU2272399A (hu)
BG (1) BG64905B1 (hu)
BR (1) BR9813604A (hu)
CA (1) CA2314965A1 (hu)
CO (1) CO4990927A1 (hu)
CZ (1) CZ299970B6 (hu)
DZ (1) DZ2680A1 (hu)
EA (1) EA002355B1 (hu)
EG (2) EG23694A (hu)
GB (1) GB9726568D0 (hu)
HR (1) HRP20000405A2 (hu)
HU (1) HUP0100500A3 (hu)
ID (1) ID24744A (hu)
IL (1) IL136381A (hu)
IN (1) IN190821B (hu)
MA (1) MA26582A1 (hu)
MY (1) MY135770A (hu)
NO (1) NO317253B1 (hu)
NZ (1) NZ504704A (hu)
OA (1) OA11634A (hu)
PE (1) PE20000057A1 (hu)
PL (1) PL341147A1 (hu)
RS (1) RS50079B (hu)
SK (1) SK286197B6 (hu)
TR (2) TR200001798T2 (hu)
TW (1) TW467913B (hu)
UA (1) UA63980C2 (hu)
UY (2) UY25305A1 (hu)
WO (1) WO1999031094A1 (hu)
ZA (1) ZA9811505B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
MXPA01010822A (es) * 1999-04-23 2002-06-04 Smithkline Beecham Plc Composicion farmaceutica novedosa.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
CA2142708A1 (en) 1992-08-28 1994-03-17 Frank Dininno Cationic-2-heteroarylphenyl-carbapenem antibacterial agents
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
TW245716B (hu) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) * 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
CZ432299A3 (cs) * 1998-06-02 2000-08-16 Smithkline Beecham Plc Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
MXPA01010822A (es) 1999-04-23 2002-06-04 Smithkline Beecham Plc Composicion farmaceutica novedosa.
CO5170421A1 (es) 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto farmaceutico maleico

Also Published As

Publication number Publication date
KR100549143B1 (ko) 2006-02-03
TR199802626A2 (xx) 1999-10-21
CN101412713A (zh) 2009-04-22
US7045633B2 (en) 2006-05-16
US20040097553A1 (en) 2004-05-20
HRP20000405A2 (en) 2000-12-31
DZ2680A1 (fr) 2005-02-20
ID24744A (id) 2000-08-03
UY25305A1 (es) 2000-12-29
AR017430A1 (es) 2001-09-05
RS50079B (sr) 2009-01-22
OA11634A (en) 2004-11-22
WO1999031094A1 (en) 1999-06-24
YU36200A (sh) 2003-12-31
BR9813604A (pt) 2000-10-10
SK286197B6 (sk) 2008-05-06
CN1281454A (zh) 2001-01-24
JP2002508372A (ja) 2002-03-19
SK9102000A3 (en) 2001-01-18
NZ504704A (en) 2003-03-28
TW467913B (en) 2001-12-11
MA26582A1 (fr) 2004-12-20
NO20003068D0 (no) 2000-06-15
IL136381A (en) 2003-09-17
EP1045847A1 (en) 2000-10-25
NO317253B1 (no) 2004-09-27
AR017213A1 (es) 2001-08-22
AU2272399A (en) 1999-07-05
CZ20002205A3 (cs) 2000-11-15
US20060189659A1 (en) 2006-08-24
PL341147A1 (en) 2001-03-26
BG104595A (en) 2001-02-28
UY25310A1 (es) 1999-07-19
GB9726568D0 (en) 1998-02-11
EA002355B1 (ru) 2002-04-25
EA200000655A1 (ru) 2000-12-25
CA2314965A1 (en) 1999-06-24
EG23694A (en) 2007-05-15
CO4990927A1 (es) 2000-12-26
AP1441A (en) 2005-07-30
KR20010033142A (ko) 2001-04-25
AP2000001830A0 (en) 2000-06-30
MY135770A (en) 2008-06-30
EG21417A (en) 2001-10-31
IN190821B (hu) 2003-08-23
NO20003068L (no) 2000-06-15
ZA9811505B (en) 2000-11-06
CZ299970B6 (cs) 2009-01-07
BG64905B1 (bg) 2006-08-31
TR200001798T2 (tr) 2000-11-21
HUP0100500A3 (en) 2002-08-28
CN101412714A (zh) 2009-04-22
PE20000057A1 (es) 2000-03-09
UA63980C2 (en) 2004-02-16
TR199802626A3 (tr) 1999-10-21
IL136381A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
HUP0100500A2 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása
HUP0300158A2 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
HUP0100509A2 (hu) Gyógyszerhatóanyagként alkalmazható 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrát, eljárás az előállításukra és gyógyászati alkalmazása
HUP0204122A2 (hu) Dioxo-tiazolidint és hetformint tartalmazó gyógyszerkészítmény és felhasználása
HUP0102292A2 (hu) Szubsztituált dioxo-tiazolidin-származékok, eljárás előállításukra és gyógyszerészeti felhasználásuk
NZ515163A (en) Thiazolidinedione derivative and its use as antidiabetic
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
WO2000063205A3 (en) Thiazolidinedione derivative and its use as antidiabetic
AP1680A (en) Thiazolidinedione derivative and its use as antidiabetic.
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
YU16303A (sh) Tartaratne soli derivata tiazolidindiona
AP2002002673A0 (en) Thiazolidinedione salt for the treatment of diabetes mellitus.
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
HUP0301799A2 (hu) 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-hidrojodid alkalmazása diabetetes mellitus kezelésére, eljárás a vegyület előállítására és ezt tartalmazó gyógyszerkészítmény
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
TH58463A (th) สารประกอบต่อต้านเบาหวานชนิดใหม่
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
TH58463B (th) สารประกอบต่อต้านเบาหวานชนิดใหม่
ECSP982779A (es) Un hidrato de la sal de acido maleico, proceso para la preparacion, composicion farmaceutica y su uso en medicina

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees